Pharmacogenetic Response to Naltrexone for Alcohol Dependence

FAQ

What is the Pharmacogenetics Study? 

The University of Pennsylvania’s Treatment Research Center is currently conducting a research study to understand the relationship between what you inherited from your family (genes), and how you respond to treatment with Naltrexone, an FDA approved medication for the treatment of alcohol dependence.

What is Naltrexone? 

Naltrexone has been shown to decrease the desire to drink and decrease the amount of heavy drinking among patients with alcohol dependence.

How long will I be involved?

Participation in the study lasts approximately 12 weeks, with participants receiving either medication (naltrexone) or placebo (inactive medication) along with individualized psychosocial support with a nurse practitioner.

Is the program confidential? 

All of the information that you provide in this project will be kept confidential. You will be assigned a confidential code number so your name will not be associated with information collected or identified anywhere in the research results.

How will I benefit from this study? 

You will receive either medication (Naltrexone) or placebo (inactive medication) and therapy for your drinking problem. You will also be contributing to our knowledge about ways to help others with alcohol use problems.

Can I choose to leave the study? 

Your participation in the study is completely voluntary. You may withdraw at any time without affecting your present or future care.

Who may be eligible?

Men and women of European or Asian descent ages 18 and older who are frequent drinkers.

Will I have to pay for my treatment?

There is no charge for any assessment, medication, treatment or lab tests you will receive in this study.

Will I be compensated?

You will be financially compensated for travel and research assessments.